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100% Response Rate to Galcanezumab in Patients With
Episodic Migraine: A Post Hoc Analysis of the Results From
Phase 3, Randomized, Double-Blind, Placebo-Controlled
EVOLVE-1 and EVOLVE-2 Studies
Noah Rosen, MD, FAHS; Eric Pearlman, MD; Dustin Ruff, PhD; Kathleen Day, MS;
Abraham Jim Nagy, MD, FAHS

Objective.—To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab
treatment.
Background.—Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide
(CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.
Methods.—A post hoc analysis of the proportion of patients with 100% response (100% reduction from baseline in monthly
MHD) was calculated for each month from pooled data of 2 double-blind, 6-month galcanezumab studies in patients with episodic
migraine (4 to 14 MHD and ≥2 migraine attacks per month at baseline). The patients were randomized (1:1:2) to monthly
subcutaneous galcanezumab, 120 mg (after 240 mg initial loading dose) or 240 mg, or placebo. A generalized linear mixed
model with effects for baseline MHD, treatment, month, and treatment-by-month interaction was used to estimate the mean
monthly response rate.
Results.—The analysis included 1739 patients treated with galcanezumab, 120 mg (n = 436) or 240 mg (n = 428), or placebo
(n = 875). The mean monthly 100% response rate on an average month in the 6-month double-blind phase was greater for galcanezumab 120 mg (13.5%) and 240 mg (14.3%) groups vs placebo (5.9%) with odds ratios of 2.5 (95% confidence interval [CI]
1.9, 3.2) and 2.6 (95% CI 2.0, 3.4), respectively (P < .001). The rate of 100% monthly response increased at each month over the
6-month double-blind phase with higher rates for galcanezumab dose groups (9 to 21%) than placebo (2 to 10%) (P < .02).
Evaluation of 100% response by the number of months showed a greater proportion of galcanezumab-treated patients in either dose
group, compared to placebo, were able to achieve a 100% response (P < .001 up to 3 months); however, though greater than placebo, few galcanezumab patients had ≥4 months of 100% response (P < .02). The proportions of patients with 100% response were
greatest in the last 3 months of the treatment. Considering the average number days between nonconsecutive MHD across the
6-month period (not just during the times of 100% response), the duration of migraine headache-free periods in the galcanezumab
groups was 29 days for those with at least 1 month of 100% response and 55 days for those with at least 3 months of 100%
response. This gap was approximately 6 to 11 times greater than the mean gap of 5 days observed at baseline.
Conclusions.—More than a third of the patients with episodic migraine treated with galcanezumab 120 mg or 240 mg
achieved 100% response for at least 1 month. More patients had 100% monthly response in the last 3 months of the 6-month
double-blind period. For those with 100% response for at least 1 month, the average time between nonconsecutive MHD for the
entire treatment period was nearly 1 month and approached 2 months for patients with 3 or more months of 100% response.
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INTRODUCTION
Migraine is a chronic neurological disease found
to be one of the top 10 causes of disease-related disability globally.1,2 Although the worldwide prevalence
of migraine and its associated medical and societal
costs are well recognized, inadequate treatment is
not uncommon.3-7 Options for preventive therapy are
limited by reasons that include lack of efficacy or intolerability to current therapies. New lines of care are
necessary to address the unmet needs of patients with
migraine who remain untreated.8-12
Patients seeking acute migraine treatment have
reported that complete pain relief and no recurrence
are important factors when considering treatment
options. Efficacy was identified by patients with migraine as the most important aspect of preventive migraine therapy.13 Guidelines from the International
Headache Society Clinical Trials Subcommittee
recommend that the achievement of ≥50% reduction
from baseline in the number of monthly migraine
headache days (MHD) or migraine attack frequency
is an important clinical measure. While the reduction of 50% or greater may seem an arbitrary choice,
it is a very clinically relevant and standard measure
in the evaluation of the effectiveness of a preventive
migraine therapy.14 Approximately 70% of the patients with migraine are non-adherent to oral preventive medications.15 One of the main reasons cited

for discontinuation is the lack of efficacy.13 Only 29%
of the patients report being very satisfied with their
current level of treatment.16 Preventive medications
with higher response rates of ≥75% reduction or 100%
reduction in MHD may improve medication adherence. Further, the opportunity for 100% reduction of
MHD may be more in line with the patient’s desires
than what has previously been available or possible.
To date, the data regarding 100% response rate with
migraine therapies are lacking. Galcanezumab is
under development for the prevention of migraine and
is a humanized monoclonal antibody that binds to the
calcitonin gene-related peptide (CGRP) and prevents
its biological activity without blocking the CGRP receptor. Two randomized, double-blind, placebo-controlled, Phase 3 studies examined the efficacy of
galcanezumab 120 mg/month and 240 mg/month in
patients with episodic migraine (studies EVOLVE-1
and EVOLVE-2).17,18 The patients treated with galcanezumab experienced on an average approximately
4 fewer MHD/month (vs 2 with placebo).17,18 In both
the trials, the mean monthly proportions of galcanezumab-treated patients who achieved a ≥50, ≥75, or
100% reduction of MHD on an average month from
baseline in the 6-month double-blind phase were
similar between the dose groups and superior to placebo. Specifically, the proportions of patients with a
≥50% reduction of MHD on an average month was
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approximately 60% of either galcanezumab 120 mg or
240 mg dose groups compared with 39% of the placebo group (P < .001). A ≥75% reduction of MHD on
an average month was achieved by approximately 34
to 39% of the patients in the galcanezumab groups
and 19% in the placebo group (P < .001). Though
lower, approximately 12 to 16% of the patients treated
with galcanezumab who achieved 100% reduction of
MHD on an average month were significantly greater
than the 6% of the placebo group (P < .001).
The results from these 2 trials demonstrated that
a good percentage of patients treated with galcanezumab were able to achieve a meaningful reduction in
MHD beyond the clinically relevant cut-off of at least a
50% reduction of MHD. The fact that the proportions
of the galcanezumab-treated patients who achieved
100% reduction of MHD, a key secondary endpoint in
the studies, was statistically significantly greater than
placebo-treated patients warranted further evaluation to better characterize the nature of the response.
The availability of data from a large population of
patients with episodic migraine treated for 6 months
allows for better characterization of efficacy with galcanezumab, the robustness of the response, and the
duration of the response over a 6-month period. More
specifically, the pooled, larger database provides an
opportunity to begin to understand what percentages
of patients respond strongly or have a minimal or
worsening response with treatment. Galcanezumab
is a new class of migraine preventive medication and
this further characterization should allow clinicians
to set appropriate expectations regarding efficacy.
Moreover, this characterization should provide clinicians with a better understanding of what this potentially means for patients given that efficacy and
complete response have been indicated as important
attributes of a preventive migraine therapy. The current analyses further characterized patients from the
EVOLVE-1 and EVOLVE-2 trials who achieved 100%
response with galcanezumab treatment.17,18

METHODS
Study Design.—Detailed descriptions of the study
design of the 2 episodic migraine 6-month double-blind
trials (ClinTrials.gov NCT02614183 and NCT02614196)
have been reported separately.17,18 Briefly, in both
trials, adult patients with episodic migraine were to
have a history of migraine of at least 1 year prior to
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study screening and onset of migraine prior to age 50.
Episodic migraine was defined as having between 4 and
14 MHD and at least 2 migraine attacks per month.5
The patients were randomized 1:1:2 and received
subcutaneous injections of galcanezumab 120 mg/month
(after a 240 mg initial loading dose) or 240 mg/month or
placebo.17,18 The patients recorded headache symptoms,
duration, and severity with an electronic diary. The
study protocol was reviewed and approved by the
appropriate institutional review board for each of the
study sites. The study was conducted according to
Good Clinical Practice and the Declaration of Helsinki
guidelines. The patients provided written informed
consent before undergoing the study procedures.
Statistical Method.—Data for the 2 trials were
pooled and were the basis of the post hoc analyses. The
analysis set consisted of 1739 adult patients with episodic
migraine and a baseline and a Month 1 MHD value.
Complete response for a given month was defined as the
proportion of patients with 100% reduction from baseline
in their MHD (ie, patients had no MHD during the
given month). Similarly, a 75% response was defined
as the proportion of patients with ≥75% reduction from
baseline in MHD in a given month. In calculating the
number of MHD for each month period, if the entry
period was not equal to 30 days, the number of MHD
was normalized by multiplying the number of MHD
by (30/x) where “x” is the total number of non-missing
diary days in the period. Additionally, if the daily diary
entry rate for any period was less than or equal to 50%,
all endpoints derived from the diary data for that period
were set to missing.
Response rates for each month and response rates
across all months were calculated using a generalized
linear mixed model with effects for study, baseline
MHD, treatment, month, and treatment-by-month
interaction.19 For each month of dosing, the number
of MHD was estimated and the determination that
the patient met response at that month was based on
either the ≥75 or 100% response definition. Hence, the
patient had a binary response (either “yes” or “no”)
at each month with non-missing number of MHD.
The rates of nonresponse (no change or worsening response) for each month were also calculated similar to
positive response rates. Nonresponse was defined as
having a monthly MHD value that was greater than
or equal to their baseline monthly MHD (ie, if their
change from baseline is ≥0).
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The models for the repeated binary outcomes
included the fixed, categorical effects of study treatment, month, and treatment-by-month interaction,
as well as the continuous, fixed covariate of baseline
value. The patient was considered a random effect in
this model and a logit link was used along with an unstructured covariance. The rates of patients achieving response for at least 1 month were summarized
by treatment with pairwise comparisons between the
treatments conducted via Fisher’s exact tests. Similar
comparisons were made for patients achieving response for at least 2, at least 3, at least 4, at least 5,
and for all 6 months. For each patient, the average
length (in days) of migraine headache-free periods
(AMHFP) between nonconsecutive MHD was calculated as the total number of days without a migraine
headache divided by the number of migraine-free
“gaps” between MHD. This calculation was done
both for the baseline period as well as for the entire
6-month double-blind period. The mean AMHFP
was calculated for all patients as well as for patients
having certain number of migraine headache-free

months (for example, patients with at least 1 month
of 100% response) to help characterize the experience
of those responding to galcanezumab treatment. All
analyses were conducted using SAS 9.4. All assessments of statistical significance are based on 2-sided
tests conducted at the 0.05 significance level.

RESULTS
Patient Disposition.—Data from 1739 adult
patients with episodic migraine treated with 120 mg
galcanezumab (n = 436), 240 mg galcanezumab
(n = 428), or placebo (n = 875) from the 2 studies were
evaluated in the analysis. The full description of patient
disposition is provided in previous publications.17,18
Table 1 presents the baseline demographics and the
disease characteristics for the 2 galcanezumab dose
groups and the placebo group. Overall, more than
80% of the patients were female and more than 74%
were white; the mean age was approximately 40
years, and the mean migraine disease duration was
20 years. At baseline, the mean number of migraine

Table 1.—Patient Demographics and Disease Characteristics of Galcanezumab-Treated Patients
From Episodic Migraine Trials
Variables
Age, years, mean (SD)
Female, n (%)
Race, white, n (%)
Body mass index, kg/m 2 mean (SD)
Migraine disease duration, years, mean (SD)
Migraine headache days (MHD)/month, mean (SD)
MHD/month with acute medication use, mean (SD)
Headache days/month, mean (SD)
Migraine headache hours/month, mean (SD)
Headache hours/month, mean (SD)
Migraine with aura, n (%)
Prior preventive treatment in past 5 years, n (%)
Failed ≥2 preventives in past 5 years, n (%)
MIDAS total, mean (SD)
MSQ RF-R, mean (SD)
MSQ RF-P, mean (SD)
MSQ EF, mean (SD)
PGI-S, mean (SD)

Placebo (N = 894)
41.9 (11.4)
755 (84.5)
681 (76.2)
27.6 (5.5)
20.5 (12.5)
9.1 (3.0)
7.5 (3.4)
10.6 (3.4)
54.5 (37.7)
59.3 (40.1)
471 (52.7)
555 (62.1)
85 (9.5)
33.1 (29.3)
52.1 (15.6)
67.9 (18.5)
62.1 (24.6)
4.3 (1.2)

Galcanezumaba (N = 879)
40.7 (11.4)
744 (84.6)
652 (74.2)
27.6 (5.5)
20.1 (12.2)
9.1 (2.9)
7.4 (3.4)
10.7 (3.7)
55.0 (39.7)
61.7 (51.9)
467 (53.1)
559 (63.6)
88 (10.0)
33.1 (28.2)
51.1 (16.1)
66.7 (19.7)
59.2 (24.0)
4.3 (1.2)

Abbreviations: EF = Emotional Function; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life
Questionnaire version 2.1; PGI-S = Patient Global Impression of Severity; RF-P = Role Function-Preventive; RF-R = Role
Function-Restrictive; SD = standard deviation.
Note: One patient did not have MHD values at Month 1 and was excluded from further analyses.
a

Pooled data from two 6-month trials in patients with episodic migraine and combined 120 mg/month and 240 mg/month
galcanezumab-treated patient groups.
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Table 2.—Baseline Migraine Headache Days and Headache Days by Number of Months With 100% Response
At Least 1
Month
(n = 171)

At Least 2
Months
(n = 74)

At Least 3
Months
(n = 48)

At Least 4
Months
(n = 22)

At Least 5
Months
(n = 6)

All 6
Months
(n = 2)

Migraine headache days, mean (SD)

8.2 (3.0)
9.9 (3.4)
At least 1
month
(n = 169)
8.2 (3.0)
9.7 (3.4)
At least 1
month
(n = 178)
8.4 (2.9)

8.2 (3.0)
9.8 (3.4)
At least 2
months
(n = 95)
8.1 (3.0)
9.5 (3.4)
At least 2
months
(n = 91)
7.9 (2.9)

7.6 (2.7)
9.2 (3.2)
At least 3
months
(n = 46)
7.8 (3.0)
9.1 (3.3)
At least 3
months
(n = 59)
7.9 (2.9)

7.3 (2.8)
8.6 (3.2)
At least 4
months
(n = 21)
7.5 (2.9)
8.6 (3.1)
At least 4
months
(n = 28)
7.9 (2.9)

5.4 (1.7)
5.6 (1.6)
At least 5
months
(n = 12)
6.6 (1.4)
7.9 (2.3)
At least 5
months
(n = 12)
7.6 (2.3)

4.5 (0.7)
4.5 (0.7)
All 6
months
(n = 3)
7.7 (1.5)
7.7 (1.5)
All 6
months
(n = 6)
7.1 (2.8)

Headache days, mean (SD)

10.5 (4.0)

9.4 (3.7)

9.7 (4.0)

9.4 (3.9)

9.6 (4.7)

9.8 (6.3)

Placebo (N = 872)
Migraine headache days, mean (SD)
Headache days, mean (SD)
Galcanezumab 120 mg (N = 435)

Migraine headache days, mean (SD)
Headache days, mean (SD)
Galcanezumab 240 mg (N = 427)

Abbreviation: SD = standard deviation.

headache days was 9.1 and number of headache days
was 10.7. The completion rates for the double-blind
portion of the 2 studies ranged from 83 to 87% across
both galcanezumab doses.17,18 The baseline MHD
days and headache days for the subgroup of patients
with 100% response by the number of months with
100% response are shown in Table 2.
Patients With 100% Response.—The mean (standard
error [SE]) monthly 100% response rate on an average
month in the 6-month double-blind phase was greater
for galcanezumab 120 mg (13.5 ± 1.1%) and 240 mg
(14.3 ± 1.1%) groups vs placebo (5.9 ± 0.5%). The 100%
response rate odds ratios were 2.5 (95% confidence interval
[CI] 1.9, 3.2) for galcanezumab 120 mg and 2.6 (95% CI 2.0,
3.4) for galcanezumab 240 mg (P < .001 for both).

Starting at Month 1, 100% response was achieved
by 9% (±1%) of the galcanezumab-treated patients
compared to 2% (±0.5%) of the placebo patients
(P < .001) and at Month 6 the rates were up to 17%
(±2%) and 21% (±2%) of the patients on galcanezumab 120 mg or 240 mg treatment, respectively, vs
10% (±1%) of the placebo patients (P < .001) (Fig. 1).
When considering the other end of the spectrum,
patients with no change or worsening response, it
is important to note that at every month within the
6-month period, the percentage of these patients was
statistically significantly larger for placebo compared
to either of the galcanezumab group. The rates ranged
from 8.6% (±1%) to 17.3% (±2%) with galcanezumab
treatment compared to 21.9% (±2%) to 32.9% (±2%)

Fig. 1.—Patients with 100% response by month. N = sample size of the treatment group.
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Fig. 2.—Patients with no change or worsening response by month. N = sample size of the treatment group.

of the patients with placebo treatment (Fig. 2). Taking
into account the proportions of patients who achieved
≥75% response on an average month in the 6-month period, the proportions of 36% (±2%) in either of the galcanezumab dose group were significantly greater than
the 19% (±1%) of the patients in the placebo group
(P < .001). Breaking down the proportions by month,
in both the galcanezumab dose groups, 25% (±2%) of
the patients achieved ≥75% response at Month 1 (as
shown in Fig. 3) compared to 9% (±1%) of the patients
in the placebo group (P < .001). By Month 6, the proportions of patients who achieved ≥75% response were
44% (±3%) in either of the galcanezumab group (Fig. 3)
and greater than the 25% (±2%) of the placebo group
(P < .001). The observed proportions of patients with
episodic migraine with 100 or ≥75% response, or no
change or worsening response are shown by month in
the online Supplemental Table 1.
Evaluation of 100% response by the number of
months with 100% response is shown in Figure 4. At
baseline, the mean number of MHD was 8 days for patients with at least 1 month of 100% response. The proportions of patients who achieved 100% response for at
least 1 month were greater for the galcanezumab 120 mg
(38.8%) and 240 mg (41.6%) dose groups compared with
the placebo group (19.5%; P < .0001). Though very few
patients had more than 4 months with 100% response,
the baseline mean number of MHD was 7 days and
the proportions of patients who attained this measure
were generally significantly greater with galcanezumab

treatment compared with placebo (P < .02). The timing
of achievement of 100% response occurred for more patients with at least 1, 2, or 3 months of 100% response
in the last 3 months (Month 4 to Month 6) of the double-blind phase than in the first 3 months (Fig. 5).
Considering the average number days between
nonconsecutive MHD across the 6-month period
(not just during the times of 100% response), the
mean average length (in days ± standard deviation)
of migraine headache-free periods in the galcanezumab groups was around 29 days (±34) for those
with at least 1 month of 100% response and around
55 days (±48) for those with at least 3 months of 100%
response (Fig. 6). For those with at least 1 month
of 100% response, this was 6 times greater than the
mean baseline gap of 5 days (±2) and close to 11 times
greater than the baseline for those who had 3 months
of 100% response. The change from baseline in the
average length (in days) of migraine headache-free
periods in patients with 100% response with at least 1,
2, or 3 months of 100% response was similar between
the galcanezumab dose groups. Breaking down the
percentages on a weekly level, the percentage of galcanezumab 120 mg and 240 mg patients vs placebo
patients achieving average migraine headache-free
day gaps for ≥1 week was 68 and 67 vs 47%, respectively; for ≥2 weeks was 35 and 33 vs 15%, respectively;
for ≥3 weeks was 19 and 17 vs 8%, respectively; and
for ≥4 weeks was 11 and 12 vs 5%, respectively. After
≥5 weeks to ≥8 weeks, the percentages of patients
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Fig. 3.—Galcanezumab-treated patients with 100 and ≥75% response by month. Illustrated here by stacked bars are patients with
≥75% response and the portion of those patients with 100% response to reflect, by month, the overall percentage of patients that
met either response measure. The percentages within each bar represent only the percentage of patients with either 100 or ≥75%
response and should not be added. Panel A and Panel B represent patients treated with galcanezumab 120 mg/month or 240 mg/
month, respectively. Asterisks denote statistical significance compared with placebo. Panel C represents patients treated with
placebo.

achieving average migraine headache-free day gaps
in the galcanezumab groups ranged from 4 to 8% vs
the 2 to 3% of the placebo group.
Overall, it is important to clarify that these results
are specific to freedom of migraine headache days
and does not infer headache-free.

DISCUSSION
Treatment with galcanezumab 120 mg or 240 mg
demonstrated a greater efficacy in achieving 100%
response in reduction of MHD compared with placebo in the 6-month double-blind phase. The proportions of galcanezumab patients who achieved 100%
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Fig. 4.—Patients with 100% response by number of months with 100% response. N = sample size of the treatment group.

Fig. 5.—Patients with 100% response in first and last 3 months by number of months with 100% response. N = sample size of the
treatment group.

response on an average month was over double that
of the placebo.
At the patient level, approximately 40% of the
galcanezumab-treated patients had at least 1 month
of 100% response in reduction of MHD. Notably,
a good number of galcanezumab-treated patients
were free of migraine headache for 2 out of the 3
months on the last 3 months of the treatment. The

proportions of patients who achieved multiple
months of 100% responses decreased as the number
of months with response increased. It is encouraging that approximately 13% of the patients had at
least 3 months of 100% response across the 6-month
phase. More patients achieved at least 1 month of
100% response in the last 3 months of treatment
than in the first 3 months. This suggests that the
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Fig. 6.—Average length (in days) of migraine headache-free periods in patients with 100% response (across Months 1- 6). Illustrated
are the mean baseline average lengths (in days) of migraine headache-free periods between migraine headache days (open bars)
and the mean number of migraine headache-free days between migraine headache days across Months 1-6 for patients treated with
galcanezumab 120 mg (red solid bar) or galcanezumab 240 mg (blue solid bar). N = sample size of the treatment group.

longer the patient remains on medication, the more
likely the patient is to have at least 1 month of 100%
response. However, it is important to point out that
this analysis specifically evaluated freedom from
migraine headache days and these results do not
imply headache-free.
The findings from this study are relevant but
must be considered in light of study limitations.
The 100% response was only captured for the month
between injections. If a patient had 30 or more
consecutive migraine headache-free days and this
occurred across a dosing cycle, this may not have
been counted as having had a month of 100% reduction of MHD. Additionally, for any patient who
discontinued the study early, only the daily diary
data up to the date of discontinuation were used.
For the analyses of the number of months with 100%
response, this effectively treated any missing month
as having had no response (although patients may
have had 30 days with a MHD after discontinuation). Both of these limitations actually represent
a potential underestimation of the percentage of
p atients showing 100% monthly response. Finally,
as with any controlled clinical trial, the generalizability of the findings among the larger population
is limited.

Complete response and no recurrence of MHD
are important attributes in preventive migraine therapies. It is well understood that patients who suffer
from migraine are burdened by factoring in considerations to accommodate impending migraine attacks. The disruptions to work, family, and social
activities caused by migraine translate into an overall poorer quality of life.13,20 In this study, patients
who had at least 1 month of 100% response had
more freedom from their migraine headaches across
the 6-month dosing period. On average, patients
treated with galcanezumab with at least a month
of 100% response gained 25 consecutive migraine
headache-free days between the few migraine headaches they did experience. Further, patients with at
least 3 out of the 6 months of 100% response averaged nearly a 2-month gap between nonconsecutive
MHD. The clinical bar of a 50% reduction on an
average month in baseline MHD is important and
provides an estimate for what a majority of patients
can expect. The higher bar of a ≥75% reduction on
an average month in baseline MHD was attained by
36% of the galcanezumab-treated patients compared
with 19% of the placebo-treated patients. However,
the fact that a smaller percentage of patients treated
with galcanezumab can achieve a 100% reduction of
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MHD coupled with longer times between nonconsecutive MHD lessens the extent to which they experience the burden of their disease.

CONCLUSIONS
Around 40% of the patients with episodic migraine treated with galcanezumab achieved 100%
response for at least 1 month. The percentages of patients with 100% response increased by month in the
6-month double-blind period; very few patients (0.7
to 1.4%) achieved 100% response for all 6 months of
the study. More patients had 100% monthly response
in the last 3 months. For those with at least 1 month
of 100% response, the average time between nonconsecutive MHD for the entire treatment period
was nearly 1 month and approached 2 months for
patients with 3 or more months of 100% response.
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